Brief: Neogenomics Launches C-Met Cdx Assay To Guide Treatment Decisions For Advanced Non-Small Cell Lung Cancer
22/05/2025 12:18
May 22 (Reuters) - Neogenomics Inc NEO.O: NEOGENOMICS LAUNCHES C-MET CDX ASSAY TO GUIDE TREATMENT DECISIONS FOR ADVANCED NON-SMALL CELL LUNG CANCER Source text: ID:nBw9p5bl1a Further company coverage: NEO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NeoGenomics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
NeoGenomics rises after BTIG upgrades to 'buy'
Brief: Neogenomics Announces Executive Leadership And Board Of Directors Succession Plan
Brief: Neogenomics Receives Medicare Coverage For Radar St For Immunotherapy Treatment Response Monitoring